Evaluation of sphinganine and sphingosine as human breast cancer chemotherapeutic and chemopreventive agents

Experimental Biology and Medicine

Volumn 231, Issue 10, 2006, Pages 1664-1672

  Eun, Hyun Ahn ^a,d   Chang, Chia Cheng ^b,c   Schroeder, Joseph J ^a  

^a Michigan State University   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Breast cancer; Differentiation; Sphinganine; Sphingosine; Stem cells

Indexed keywords

MASPIN; SPHINGANINE; SPHINGOSINE; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; BREAST RECONSTRUCTION; CANCER CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENIC ACTIVITY; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IC 50; PHENOTYPE; PROTEIN EXPRESSION;

SPHINGOIDEA;

EID: 33751324338     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/153537020623101012     Document Type: Article

References (52)

1. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society, 1999.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics. CA Cancer J. Clin 54:8-29, 2004.
3. Ahn EH, Schroeder JJ. Bioactive sphingolipids are constituents of milk and soy products. J Food Sci 67:522-524, 2002.
4. Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill AH Jr. Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr 129:1239-1250, 1999.
5. Nilsson A. Metabolism of sphingomyelin in the intestinal tract of the rat. Biochim Biophys Acta 164:575-584, 1968.
6. Schmelz EM, Crall KJ, Larocque R, Dillehay DL, Merrill AH Jr. Uptake and metabolism of sphingolipids in isolated intestinal loops. J Nutr 124:702-712, 1994.
7. Nyberg L, Nilson A, Lundgren P, Duan R-D. Localization and capacity of sphingomyelin digestion in the rat intestinal tract. J Nutr Biochem 8:112-118, 1997.
8. Imaizumi K, Tominaga A, Sato M, Sugano M. Effects of dietary sphingolipids on levels of serum and liver lipids in rats. Nutr Res 12:543-548, 1992.
9. Wang E, Ross PF, Wilson TM, Riley RT, Merrill AH Jr. Increases in serum sphingosine and sphinganine and decreases in complex sphingolipids in ponies given feed containing fumonisins, mycotoxins produced by fusarium moniliforme. J Nutr 122:1706-1716, 1992.
10. Abnet CC, Borkowf CB, Qiao Y-L, Albert PS, Wang E, Merrill AH Jr, Mark SD, Dong Z-W, Taylor PR, Dawsey SM. A cross-sectional study of human serum sphingolipids, diet and physiologic parameters. J Nutr 131:2748-2752, 2001.
11. Ahn EH, Schroeder JJ. Sphingoid bases and ceramide induce apoptosis in HT-29 and HCT-116 human colon cancer cells. Exp Biol Med 227:345-353, 2002.
12. Sweeney EA, Sakakura C, Shirahama T, Masamune A, Ohta H, Hakomori S-I, Yasuyuki J. Sphingosine and its methylated derivative N,N-dimethlysphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer 66:358-366, 1996.
13. Cai Z, Bettaieb A, Mahdani NE, Legres LG, Stancou R, Maslliah J, Chouaib S. Alteration of the sphingomylein/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-mediated cytotoxicity. J Biol Chem 272:6918-6926, 1997.
14. Gill ZP, Perks CM, Newcomb PV, Holly JM. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 272:25602-25607, 1997.
15. Dillehay DL, Webb SK, Schmelz EM, Merrill AH Jr. Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J Nutr 124:615-620, 1994.
16. Schmelz EM, Dillehay DL, Webb SK, Reiter A, Adams J, Merrill AH Jr. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res 56:4936-4941, 1996.
17. Schmelz EM, Bushnev AS, Dillehay DL, Liotta DC, Merrill AH Jr. Suppression of aberrant colonic crypt foci by synthetic sphingomyelins with saturated or unsaturated sphingoid base backbones. Nutr Cancer 28:81-85, 1997.
18. Schmelz EM, Sullards MS, Dillehay DL, Merrill AH Jr. Colonic cell proliferation and aberrant crypt formation are inhibited by dairy glycosphingolipids in 1,2-dimethylhydrazine-treated CF1 mice. J Nutr 130:522-527, 2000.
19. Lemonnier LA, Dillehay DL, Vespremi MJ, Abrams J, Brody E, Schmelz EM. Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Arch Biochem Biophys 419:129-138, 2003.
20. Min/+ mice. J Nutr 134:1157-1161, 2004.
21. Schmelz EM, Roberts PC, Kustin EM, Lemonnier LA, Sullards MC, Dillehay DL, Merrill AH Jr. Modulation of intracellular β-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res 61:6723-6729, 2001.
22. Sakakura C, Sweeney EA, Shirahama T, Hagiwara A, Yamaguchi T, Takahashi T, Hakomori S, Igarashi Y. Selectivity of sphingosine-induced apoptosis: lack of activity of DL-erythro-dihydrosphingosine. Biochem Biophys Res Commun 246:827-830, 1998.
23. 2-ceramides induced apoptosis in human leukemia cells. Arch Pharm Res 24:144-149, 2001.
24. Goswami R, Dawson G. Does ceramide play a role in neuronal cell apoptosis? J Neurosci Res 60:141-149, 2000.
25. Radin NS. Apoptotic death by ceramide: will the real killer please stand up? Med Hypotheses 57:96-100, 2000.
26. Kao CY, Nomata K, Oakley CS, Welsch CW, Chang CC. Two types of normal human breast epithelial cells derived from reduction mammoplasty: phenotypic characterization and responses to SV 40 transfection. Carcinogenesis 16:531-538, 1995.
27. Chang CC, Sun W, Cruz A, Satoh M, Tai M-H, Trosko JE. A human breast epithelial cell type with stem cell characteristics as target cells for carcinogenesis. Radiat Res 155:201-207, 2001.
28. Kang K-S, Morita I, Cruz A, Jeon YJ, Trosko JE, Chang CC. Expression of estrogen receptors in a normal human breast epithelial cell type with luminal and stem cell characteristics and its neoplastically transformed cell lines. Carcinogenesis 18:251-257, 1997.
29. Kao CY, Oakley CS, Welsch CW, Chang CC. Growth requirements and neoplastic transformation of two types of normal human breast epithelial cells derived from reduction mammoplasty. In Vitro Cell Dev Biol Anim 33:282-288, 1997.
30. Kang KS, Sun W, Nomata K, Morita I, Cruz A, Liu CJ, Trosko JE, Chang CC. Involvement of tyrosine phosphorylation of p185 (c-erbB2/neu) in tumorigenicity induced by x-rays and the neu oncogene in human breast ephithelial cells. Mol Carcinog 21:225-233, 1998.
31. Sun W, Kang KS, Morita I, Trosko JE, Chang CC. High susceptibility of a human breast epithelial cell type with stem cell characteristics to telomerase activation and immortalization. Cancer Res 59:6118-6123, 1999.
32. Crawford KW, Bittman R, Chun J, Byun HS, Bowen WD. Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cell Mol Biol 49:1017-1023, 2003.
33. Sugawara T, Kinoshita M, Ohnishi M, Nagata J. Digestion of maize sphingolipids in rats and uptake of sphingadienine by Caco-2 cells. J Nutr 133:2777-2782, 2003.
34. Frankfurt OS, Sugarbarker EV, Robb JA, Villa L. Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors. Cancer Lett 97:149-154, 1995.
35. Perry RR, Kang Y, Greaves BS. Effects of tamoxifen on growth and apoptosis of estrogen- dependent and -independent human breast cancer cells. Ann Surg Oncol 2:238-245, 1995.
36. Gelmann EP. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog? J Natl Cancer Inst 88:224-226, 1996.
37. Mandlekar S, Yu R, Tan TH, Kong AN. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60:5995-6000, 2000.
38. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Natl Cancer Inst 93:347-357, 2001.
39. Chang, CC. Recent translational research: stem cells as the root of breast cancer. Breast Cancer Res 8:103 (doi:10.1186/bcr1385), 2006.
40. 3 in HL-60 cells. J Biol Chem 264:19076-19080, 1989.
41. 3-induced HL-60 cell differentiation. J Biol Chem 265:15823-15831, 1990.
42. Kim MY, Linardic C, Obeid L, Hannun Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor α and γ-interferon-specific role in differentiation. J Biol Chem 266:484-489, 1991.
43. Toman RE, Spiegel S, Faden AI. Role of ceramide in neuronal cell death and differentiation. J Neurotrauma 17:891-898, 2000.
44. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 1485:63-99, 2000.
45. Buccoliero R, Futerman AH. The roles of ceramide and complex sphingolipids in neuronal cell function. Pharm Res 47:409-419, 2003.
46. Hui EKW, Yang YH, Yung Y. Schedule-dependent sphinganine potentiation of retinoic acid-induced differentiation, cell-growth inhibition, and nucleophosmin translocation in a human leukemia-cell line (HL-60). Exp Hematol 20:454-461, 1992.
47. Saitoh M. Maspin, a tumor suppressor gene, is expressed in human basal breast epithelial cells but not in breast epithelial stem cells and breast cancer cells. MS thesis, Michigan State University, 2004.
48. Park JS, Noh DY, Kim SH, Kim SH, Kong G, Chang CC, Lee YS, Trosko JE, Kang KS. Gene expression analysis in SV40-immortalized human breast luminal epithelial cells with stem cell characteristics using a cDNA microarray. Int J Oncol 24:1545-1558, 2004.
49. Maass N, Nagasaki K, Ziebart M, Mundhenke C, Jonat W. Expression and regulation of tumor suppressor gene maspin in breast cancer. Clin Breast Cancer 3:281-287, 2002.
50. Shi HY, Liang R, Templeton NS, Zhang M. Inhibition of breast tumor progression by systemic delivery of the maspin gene in a syngeneic tumor model. Mol Ther 5:755-761, 2002.
51. Shi HY, Zhang W, Liang R, Kittrell F, Templeton NS, Medina D, Zhang M. Modeling human breast cancer metastasis in mice: maspin as a paradigm. Histol Histopathol 18:201-206, 2003.
52. Tai M-H, Chang CC, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26:495-502, 2005.